Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain

New Biotechnology

Volumn 25, Issue 6, 2009, Pages 417-423

  Vernet, Erik ^a   Lundberg, Emma ^a   Friedman, Mikaela ^a   Rigamonti, Nicolò ^a   Klausing, Sandra ^a   Nygren, Per Åke ^a   Gräslund, Torbjörn ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LYSATES; CELL SURFACES; EPIDERMAL GROWTH FACTOR RECEPTORS; FLUORESCENT STAINING; HIGH AFFINITY; KINASE DOMAINS; LOCALISATION; PROLIFERATION RATE; SPECIFIC INTERACTION; SURFACE DEPLETION;

AMINES; AMINO ACIDS; CELL MEMBRANES; ORGANIC ACIDS; PEPTIDES; PHOSPHORYLATION;

BIOACTIVITY;

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE;

ARTICLE; CELL DENSITY; CELL LYSATE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SECRETORY VESICLES;

EID: 70449523599     PISSN: 18716784     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbt.2009.02.001     Document Type: Article

References (38)

1. Jorissen R.N., et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284 (2003) 31-53
2. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
3. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 Suppl. 4 (2001) S3-8
4. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
5. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer 11 (2004) 689-708
6. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl. 4 (2001) S9-15
7. Giaccone G., and Rodriguez J.A. EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nat. Clin. Pract. Oncol. 2 (2005) 554-561
8. Wheeler Y.Y., Chen S.Y., and Sane D.C. Intrabody and intrakine strategies for molecular therapy. Mol. Ther. 8 (2003) 355-366
9. Hawkins P.G., and Morris K.V. RNA and transcriptional modulation of gene expression. Cell Cycle 7 (2008) 602-607
10. Lobato M.N., and Rabbitts T.H. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr. Mol. Med. 4 (2004) 519-528
11. Stocks M. Intrabodies as drug discovery tools and therapeutics. Curr. Opin. Chem. Biol. 9 (2005) 359-365
12. Boldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J. Cell. Mol. Med. 11 (2007) 54-70
13. Munro S., and Pelham H.R. A C-terminal signal prevents secretion of luminal ER proteins. Cell 48 (1987) 899-907
14. Lewis M.J., and Pelham H.R. A human homologue of the yeast HDEL receptor. Nature 348 (1990) 162-163
15. Cabrera M., et al. The retrieval function of the KDEL receptor requires PKA phosphorylation of its C-terminus. Mol. Biol. Cell 14 (2003) 4114-4125
16. Orlova A., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66 (2006) 4339-4348
17. Vernet E., et al. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. J. Immunol. Methods 338 (2008) 1-6
18. Friedman M., et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng. Des. Sel. 23 (2007) 23
19. Friedman M., et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J. Mol. Biol. 376 (2008) 1388-1402
20. Nordberg E., et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol. Rep. 19 (2008) 853-857
21. Klein C., Bueler H., and Mulligan R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191 (2000) 1699-1708
22. Gunneriusson E., et al. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng. 12 (1999) 873-878
23. Nord K., et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 15 (1997) 772-777
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
25. Visintin M., et al. Intracellular antibodies for proteomics. J. Immunol. Methods 290 (2004) 135-153
26. Jannot C.B., et al. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13 (1996) 275-282
27. Graus-Porta D., et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16 (1997) 1647-1655
28. Jendreyko N., et al. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J. Biol. Chem. 278 (2003) 47812-47819
29. Jendreyko N., et al. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 8293-8298
30. Beerli R.R., et al. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15 (1995) 6496-6505
31. Graus-Porta D., Beerli R.R., and Hynes N.E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 15 (1995) 1182-1191
32. Harrington M., Pond-Tor S., and Boney C.M. Role of epidermal growth factor and ErbB2 receptors in 3T3-L1 adipogenesis. Obesity (Silver Spring) 15 (2007) 563-571
33. Chattopadhyay A., et al. The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor. J. Biol.Chem. 274 (1999) 26091-26097
34. Marais R., et al. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280 (1998) 109-112
35. Haluska P., et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7 9 (2008) 2589-2598
36. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5 (2007) 203-220
37. Lu D., et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280 (2005) 19665-19672
38. Ronnmark J., et al. Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J. Immunol. Methods 261 (2002) 199-211